Wanglong Qiu1, Sophia M Tang2, Sohyae Lee2, Andrew T Turk3, Anthony N Sireci3, Anne Qiu2, Christian Rose4, Chuangao Xie2, Jan Kitajewski5, Hui-Ju Wen6, Howard C Crawford6, Peter A Sims7, Ralph H Hruban8, Helen E Remotti3, Gloria H Su9. 1. The Department of Pathology, Columbia University Medical Center, New York, New York; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York. 2. Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York. 3. The Department of Pathology, Columbia University Medical Center, New York, New York. 4. Plexus Medical Art, Denver, Colorado. 5. Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, New York. 6. Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, Florida. 7. Department of Systems Biology, Columbia University Medical Center, New York, New York. 8. The Sol Goldman Pancreatic Cancer Research Center, Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland. 9. The Department of Pathology, Columbia University Medical Center, New York, New York; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Department of Otolaryngology and Head and Neck Surgery, Columbia University Medical Center, New York, New York. Electronic address: gs2157@columbia.edu.
Abstract
BACKGROUND & AIMS: Activin, a member of the transforming growth factor-β (TGFB) family, might be involved in pancreatic tumorigenesis, similar to other members of the TGFB family. Human pancreatic ductal adenocarcinomas contain somatic mutations in the activin A receptor type IB (ACVR1B) gene, indicating that ACVR1B could be a suppressor of pancreatic tumorigenesis. METHODS: We disrupted Acvr1b specifically in pancreata of mice (Acvr1b(flox/flox);Pdx1-Cre mice) and crossed them with LSL-KRAS(G12D) mice, which express an activated form of KRAS and develop spontaneous pancreatic tumors. The resulting Acvr1b(flox/flox);LSL-KRAS(G12D);Pdx1-Cre mice were monitored; pancreatic tissues were collected and analyzed by histology and immunohistochemical analyses. We also analyzed p16(flox/flox);LSL-Kras(G12D);Pdx1-Cre mice and Cre-negative littermates (controls). Genomic DNA, total RNA, and protein were isolated from mouse tissues and primary pancreatic tumor cell lines and analyzed by reverse-transcription polymerase chain reaction, sequencing, and immunoblot analyses. Human intraductal papillary mucinous neoplasm (IPMN) specimens were analyzed by immunohistochemistry. RESULTS: Loss of ACVR1B from pancreata of mice increased the proliferation of pancreatic epithelial cells, led to formation of acinar to ductal metaplasia, and induced focal inflammatory changes compared with control mice. Disruption of Acvr1b in LSL-KRAS(G12D);Pdx1-Cre mice accelerated the growth of pancreatic IPMNs compared with LSL-KRAS(G12D);Pdx1-Cre mice, but did not alter growth of pancreatic intraepithelial neoplasias. We associated perinuclear localization of the activated NOTCH4 intracellular domain to the apical cytoplasm of neoplastic cells with the expansion of IPMN lesions in Acvr1b(flox/flox);LSL-KRAS(G12D);Pdx1-Cre mice. Loss of the gene that encodes p16 (Cdkn2a) was required for progression of IPMNs to pancreatic ductal adenocarcinomas in Acvr1b(flox/flox);LSL-Kras(G12D);Pdx1-Cre mice. We also observed progressive loss of p16 in human IPMNs of increasing grades. CONCLUSIONS: Loss of ACVR1B accelerates growth of mutant KRAS-induced pancreatic IPMNs in mice; this process appears to involve NOTCH4 and loss of p16. ACVR1B suppresses early stages of pancreatic tumorigenesis; the activin signaling pathway therefore might be a therapeutic target for pancreatic cancer.
BACKGROUND & AIMS:Activin, a member of the transforming growth factor-β (TGFB) family, might be involved in pancreatic tumorigenesis, similar to other members of the TGFB family. Humanpancreatic ductal adenocarcinomas contain somatic mutations in the activin A receptor type IB (ACVR1B) gene, indicating that ACVR1B could be a suppressor of pancreatic tumorigenesis. METHODS: We disrupted Acvr1b specifically in pancreata of mice (Acvr1b(flox/flox);Pdx1-Cremice) and crossed them with LSL-KRAS(G12D) mice, which express an activated form of KRAS and develop spontaneous pancreatic tumors. The resulting Acvr1b(flox/flox);LSL-KRAS(G12D);Pdx1-Cremice were monitored; pancreatic tissues were collected and analyzed by histology and immunohistochemical analyses. We also analyzed p16(flox/flox);LSL-Kras(G12D);Pdx1-Cremice and Cre-negative littermates (controls). Genomic DNA, total RNA, and protein were isolated from mouse tissues and primary pancreatic tumor cell lines and analyzed by reverse-transcription polymerase chain reaction, sequencing, and immunoblot analyses. Humanintraductal papillary mucinous neoplasm (IPMN) specimens were analyzed by immunohistochemistry. RESULTS: Loss of ACVR1B from pancreata of mice increased the proliferation of pancreatic epithelial cells, led to formation of acinar to ductal metaplasia, and induced focal inflammatory changes compared with control mice. Disruption of Acvr1b in LSL-KRAS(G12D);Pdx1-Cremice accelerated the growth of pancreatic IPMNs compared with LSL-KRAS(G12D);Pdx1-Cremice, but did not alter growth of pancreatic intraepithelial neoplasias. We associated perinuclear localization of the activated NOTCH4 intracellular domain to the apical cytoplasm of neoplastic cells with the expansion of IPMN lesions in Acvr1b(flox/flox);LSL-KRAS(G12D);Pdx1-Cremice. Loss of the gene that encodes p16 (Cdkn2a) was required for progression of IPMNs to pancreatic ductal adenocarcinomas in Acvr1b(flox/flox);LSL-Kras(G12D);Pdx1-Cremice. We also observed progressive loss of p16 in human IPMNs of increasing grades. CONCLUSIONS: Loss of ACVR1B accelerates growth of mutant KRAS-induced pancreatic IPMNs in mice; this process appears to involve NOTCH4 and loss of p16. ACVR1B suppresses early stages of pancreatic tumorigenesis; the activin signaling pathway therefore might be a therapeutic target for pancreatic cancer.
Authors: Kristian L Jones; Ashley Mansell; Shane Patella; Bernadette J Scott; Mark P Hedger; David M de Kretser; David J Phillips Journal: Proc Natl Acad Sci U S A Date: 2007-10-02 Impact factor: 11.205
Authors: Toru Furukawa; Günter Klöppel; N Volkan Adsay; Jorge Albores-Saavedra; Noriyoshi Fukushima; Akira Horii; Ralph H Hruban; Yo Kato; David S Klimstra; Daniel S Longnecker; Jutta Lüttges; G Johan A Offerhaus; Michio Shimizu; Makoto Sunamura; Arief Suriawinata; Kyoichi Takaori; Suguru Yonezawa Journal: Virchows Arch Date: 2005-08-09 Impact factor: 4.064
Authors: Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho Journal: Genes Dev Date: 2003-12-17 Impact factor: 11.361
Authors: Nabeel Bardeesy; Andrew J Aguirre; Gerald C Chu; Kuang-Hung Cheng; Lyle V Lopez; Aram F Hezel; Bin Feng; Cameron Brennan; Ralph Weissleder; Umar Mahmood; Douglas Hanahan; Mark S Redston; Lynda Chin; Ronald A Depinho Journal: Proc Natl Acad Sci U S A Date: 2006-04-03 Impact factor: 11.205
Authors: Jens T Siveke; Clara Lubeseder-Martellato; Marcel Lee; Pawel K Mazur; Hassan Nakhai; Freddy Radtke; Roland M Schmid Journal: Gastroenterology Date: 2007-11-04 Impact factor: 22.682
Authors: Barbara Jung; Jessica Gomez; Eddy Chau; Jennifer Cabral; Jeffrey K Lee; Aimee Anselm; Przemyslaw Slowik; Deena Ream-Robinson; Karen Messer; Judith Sporn; Sung K Shin; C Richard Boland; Ajay Goel; John M Carethers Journal: PLoS One Date: 2009-12-14 Impact factor: 3.240
Authors: Janel L Kopp; Claire L Dubois; David F Schaeffer; Atefeh Samani; Farnaz Taghizadeh; Robert W Cowan; Andrew D Rhim; Bangyan L Stiles; Mark Valasek; Maike Sander Journal: Gastroenterology Date: 2017-12-19 Impact factor: 22.682
Authors: Wanglong Qiu; Helen E Remotti; Sophia M Tang; Elizabeth Wang; Lily Dobberteen; Ayman Lee Youssof; Joo Hee Lee; Edwin C Cheung; Gloria H Su Journal: Cancer Lett Date: 2018-03-08 Impact factor: 8.679
Authors: Ulrika A Hänninen; Riku Katainen; Tomas Tanskanen; Roosa-Maria Plaketti; Riku Laine; Jiri Hamberg; Ari Ristimäki; Eero Pukkala; Minna Taipale; Jukka-Pekka Mecklin; Linda M Forsström; Esa Pitkänen; Kimmo Palin; Niko Välimäki; Netta Mäkinen; Lauri A Aaltonen Journal: PLoS Genet Date: 2018-03-09 Impact factor: 5.917